Table I.
GO-BP terms and KEGG pathways enriched by upregulated genes.
A, GO-BP terms | |||
---|---|---|---|
Term | Description | Count | P-value |
GO:0015837 | Amine transport | 5 | 5.95×10−3 |
GO:0006865 | Amino acid transport | 4 | 1.78×10−2 |
GO:0007167 | Enzyme-linked receptor protein signaling pathway | 7 | 1.85×10−2 |
GO:0051674 | Localization of cell | 6 | 4.03×10−2 |
GO:0048870 | Cell motility | 6 | 4.03×10−2 |
GO:0035239 | Tube morphogenesis | 4 | 4.32×10−2 |
GO:0001501 | Skeletal system development | 6 | 4.62×10−2 |
GO:0035295 | Tube development | 5 | 4.63×10−2 |
B, Enriched KEGG pathways | |||
Term | Description | Count | P-value |
hsa04012 | ErbB signaling pathway | 3 | 8.21×10−2 |
hsa05216 | Thyroid cancer | 2 | 1.48×10−1 |
hsa00512 | O-glycan biosynthesis | 2 | 1.53×10−1 |
hsa04514 | CAMs | 3 | 1.64×10−1 |
hsa00071 | Fatty acid metabolism | 2 | 1.99×10−1 |
hsa05219 | Bladder cancer | 2 | 2.08×10−1 |
hsa05213 | Endometrial cancer | 2 | 2.51×10−1 |
hsa05221 | Acute myeloid leukemia | 2 | 2.75×10−1 |
hsa03320 | PPAR signaling pathway | 2 | 3.19×10−1 |
hsa04810 | Regulation of actin cytoskeleton | 3 | 3.33×10−1 |
hsa04350 | TGF-β signaling pathway | 2 | 3.84×10−1 |
hsa04060 | Cytokine-cytokine receptor interaction | 3 | 4.27×10−1 |
hsa05200 | Pathways in cancer | 3 | 5.48×10−1 |
hsa04310 | Wnt signaling pathway | 2 | 5.71×10−1 |
hsa04144 | Endocytosis | 2 | 6.45×10−1 |
hsa04510 | Focal adhesion | 2 | 6.78×10−1 |
hsa04080 | Neuroactive ligand-receptor interaction | 2 | 7.66×10−1 |
hsa04010 | MAPK signaling pathway | 2 | 7.80×10−1 |
hsa04740 | Olfactory transduction | 2 | 8.86×10−1 |
Term, identification number of GO term or KEGG pathway; Description, name of GO term or KEGG pathway; Count, number of genes enriched in GO term or KEGG pathway; GO, Gene Oncology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CAMs, cell adhesion molecules; MAPK, mitogen-activated protein kinase; TGF-β, transforming growth factor-β; PPAR, peroxisome proliferator-activated receptor.